Skip to content
10-Q

Quarterly Report

REIN THERAPEUTICS, INC. RNTX

0001193125-26-225352

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 85.54M sh
Shares Diluted Q1 2026 · Mar 31, 2026 30.35M sh
Shares Diluted Q1 2026 · Mar 31, 2025 21.92M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.42M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$6.18M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $4.45M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $3.22M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $7.43M
Cash And Equivalents Q1 2026 · Dec 31, 2024 $12.87M
Stockholders Equity Q1 2026 · Mar 31, 2026 $11.59M
Stockholders Equity Q1 2026 · Dec 31, 2025 $16.92M
Stockholders Equity Q1 2026 · Mar 31, 2025 $49.88M
Stockholders Equity Q1 2026 · Dec 31, 2024 $54.39M
Current Liabilities Q1 2026 · Mar 31, 2026 $13.64M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.18M
Total Liabilities Q1 2026 · Mar 31, 2026 $14.7M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.24M
Current Assets Q1 2026 · Mar 31, 2026 $5.45M
Current Assets Q1 2026 · Dec 31, 2025 $4.33M
Total Assets Q1 2026 · Mar 31, 2026 $26.29M
Total Assets Q1 2026 · Dec 31, 2025 $24.16M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.19
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.25
Eps Basic Q1 2026 · Mar 31, 2026 −$0.19
Eps Basic Q1 2026 · Mar 31, 2025 −$0.25
Sga Expense Q1 2026 · Mar 31, 2026 $2.16M
Sga Expense Q1 2026 · Mar 31, 2025 $2.56M
Rd Expense Q1 2026 · Mar 31, 2026 $3.07M
Rd Expense Q1 2026 · Mar 31, 2025 $3.05M
Net Income Q1 2026 · Mar 31, 2026 −$5.84M
Net Income Q1 2026 · Mar 31, 2025 −$5.5M
Operating Income Q1 2026 · Mar 31, 2026 −$5.23M
Operating Income Q1 2026 · Mar 31, 2025 −$5.61M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $0